Combining their expertise in protein engineering and synthetic DNA technology, scientists at the Wistar Institute in Philadelphia have successfully delivered nanoparticle antitumor vaccines that stimulated robust T cell immunity and controlled melanoma growth in preclinical models. The vaccines, which displayed 60 copies of protein parts derived from melanoma-specific antigens, were tested in mouse models of melanoma and resulted in prolonged survival that depended on T cell activation.
An official website of the United States government.